Log In
BCIQ
Print this Print this
 

MEDI0700

  Manage Alerts
Collapse Summary General Information
Company AstraZeneca plc
DescriptionBispecifoc mAb targeting BLyS (BAFF) and inducible T cell co-stimulator ligand (ICOSLG; B7-H2; B7RP1)
Molecular Target BLyS (BAFF) ; Inducible T cell co-stimulator ligand (ICOSLG) (B7-H2) (B7RP1)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationLupus
Indication DetailsTreat systemic lupus erythematosus (SLE)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today